Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata

Exclusion Criteria

• •1. Allergy or intolerance to Restylane® or hyaluronate preparations
• •2. Allergy or intolerance to triamcinolone acetonide, 10 mg/cc.
• •3. Underlying disease that might be adversely affected by Restylane® or triamcinolone (ex. patients with bleeding disorders).
• •4. Immunosuppressed patients (history of transplantation, cancer, chemotherapy, splenectomy, HIV).
• •5. Pregnant or lactating female.
• •6. Application of topical immunomodulatory or immunosuppressive agent in the preceding 6 weeks.
• •7. Systemic administration of corticosteroid or other systemic treatment (i.e. prednisone) that has immunomodulatory or other immunosuppressive mechanism of action, in the preceding 8 weeks.
• •8. Clinical evidence of secondary skin infection (i.e., folliculitis).
• •9. Other inflammatory or infectious skin disease that might interfere with evaluations during the study.
• •10. Investigational medications within the past 30 days.
• •11. Patients with susceptibility to keloid formation.
• •12. Severe allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies
• •13. Patients with allergies to gram positive bacterial proteins
• •14. Unable to give consent.